Literature DB >> 23138614

Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

David A Clark1.   

Abstract

Concern has been raised about an increased risk of lymphoma and skin cancers in patients with rheumatoid arthritis due to administration of anti-TNF-α drugs. Meta-analysis of observational data from registries as well as from randomized controlled trials has failed to show a significant increase in the risk of lymphoma when the sample size has been sufficiently large; skin cancer risk may represent a valid concern. Issues relating to interpretation of these data are discussed.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23138614     DOI： 10.1007/s10787-012-0158-0

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN： 0925-4692            Impact factor:   4.473


  11 in total

1.  The end of evidence-based medicine?

Authors:  David A Clark
Journal:  Inflammopharmacology       Date:  2012-01-19       Impact factor: 4.473

2.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Authors:  Soko Setoguchi; Daniel H Solomon; Michael E Weinblatt; Jeffrey N Katz; Jerry Avorn; Robert J Glynn; E Francis Cook; Greg Carney; Sebastian Schneeweiss
Journal:  Arthritis Rheum       Date:  2006-09

Review 3.  Immunosuppressive chemotherapy and malignancy.

Authors:  R S Schwartz
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

4.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

Review 5.  Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

Authors:  D H Solomon; E Mercer; A Kavanaugh
Journal:  Arthritis Rheum       Date:  2012-01

6.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Authors:  Johan Askling; Ronald F van Vollenhoven; Fredrik Granath; Pauline Raaschou; C Michael Fored; Eva Baecklund; Christina Dackhammar; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2009-11

7.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-09

8.  Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.

Authors:  Francesca Bobbio Pallavicini; Roberto Caporali; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Chiara Bazzani; Roberto Gorla; Antonio Marchesoni; Ennio Giulio Favalli; Carlomaurizio Montecucco
Journal:  Autoimmun Rev       Date:  2009-07-30       Impact factor: 9.754

9.  Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.

Authors:  X Mariette; F Tubach; H Bagheri; M Bardet; J M Berthelot; P Gaudin; D Heresbach; A Martin; T Schaeverbeke; D Salmon; M Lemann; O Hermine; M Raphael; P Ravaud
Journal:  Ann Rheum Dis       Date:  2009-10-14       Impact factor: 19.103

10.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.

Authors:  Maria A Lopez-Olivo; Jean H Tayar; Juan A Martinez-Lopez; Eduardo N Pollono; Jose Polo Cueto; M Rosa Gonzales-Crespo; Stephanie Fulton; Maria E Suarez-Almazor
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272
View more
  2 in total

Review 1.  Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Authors:  Sujani Yadlapati; Petros Efthimiou
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

2.  Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Authors:  Yoshiya Tanaka; Shintaro Hirata; Satoshi Kubo; Shunsuke Fukuyo; Kentaro Hanami; Norifumi Sawamukai; Kazuhisa Nakano; Shingo Nakayamada; Kunihiro Yamaoka; Fusae Sawamura; Kazuyoshi Saito
Journal:  Ann Rheum Dis       Date:  2013-11-28       Impact factor: 19.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.